Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Martin Breen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Beta
- 0.91
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -185.68
Financials
Net Income
$-4.52MEBITDA
$-4.45MFree Cash Flow
$-4.26MEPS (diluted)
$-3.00Shares Outstanding (diluted)
1.55M+22183128.6%Operating Expenses
$4.47MCash & Debt
$4.96MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-28.35M | $-156.25 |
| 2024 | $0.00 | $-13.16M | $-173.50 |
| 2023 | $0.00 | $-7.60M | $-141.00 |
| 2022 | $0.00 | $-20.88M | $-16.50 |
| 2021 | $0.00 | $-58.01M | $-51.50 |
| 2020 | $0.00 | $-28.30M | $-161.25 |
| 2019 | $0.00 | $-38.65M | $-285.50 |
| 2018 | $0.00 | $-259.19M | $-2192.50 |
| 2017 | $0.00 | $-144.17M | $-3630.50 |
| 2016 | $0.00 | $9.77M | $1530000.00 |
| 2015 | $27.0K | $-21.46M | $-35718333.25 |
| 2014 | $61.0K | $-23.49M | $-38250000.00 |
| 2013 | $368.0K | $-501.0K | $-894642.75 |
| 2012 | $342.0K | $-5.17M | $-9944230.75 |
Valuation
GTBPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·21d ago·Negative
… anticipated to provide sufficient cash runway into Q3 2027 SAN FRANCISCO, CALIFORNIA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced IND clearance from the FDA for GTB-5550 in multiple myeloma.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…of TriKE® Platform for Cancer Treatment, September 11, 2026 SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
GT Biopharma Reports Second Quarter 2026 Financial Results Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-2.50 per share
Typical surprise +94.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-3.00 vs $-2.00miss
- Thu, May 21$-0.11 vs $-2.00beat
- Mon, Mar 2$-55.50 vs $-5.50miss
- Thu, Nov 13$-0.83 vs $-9.50beat
- Wed, Aug 13$-0.55 vs $-17.00beat
- Wed, May 21$-0.33 vs $-16.00beat
Estimates and results for GTBP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GTBP officers and directors.
- Bought
- $76k
- Sold
- $205.0bn
5 trades
23 trades
- Breen Michael Martinbought
- Ohri Manubought
- Wendel Brucebought
- Wendel Brucebought
- Weldon Steven Wsold
- Weldon Steven Wsold
- Weldon Steven Wsold
- Weldon Steven Wsold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GTBP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.